← Back to Screener
Bright Minds Biosciences Inc. Common Stock (DRUG)
Price$81.02
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)34.25%
Price vs S&P 500 (4W)-1.99%
VGM Score52.96
Market Capitalization$875.74M
All Metrics
Book Value / Share (Quarterly)$8.31
P/TBV (Annual)5.45x
Cash Flow / Share (Quarterly)$-1.21
Price vs S&P 500 (YTD)2.10%
EPS (TTM)$-1.98
10-Day Avg Trading Volume0.00M
EPS Excl Extra (TTM)$-1.98
EPS (Annual)$-1.29
ROI (Annual)-14.88%
Cash / Share (Quarterly)$8.29
ROA (Last FY)-14.49%
EBITD / Share (TTM)$-1.93
ROE (5Y Avg)-69.97%
Cash Flow / Share (Annual)$-0.83
P/B Ratio13.53x
P/B Ratio (Quarterly)9.36x
Net Interest Coverage (TTM)-1324.94x
ROA (TTM)-27.92%
EPS Incl Extra (Annual)$-1.29
Current Ratio (Annual)36.10x
Quick Ratio (Quarterly)56.59x
3-Month Avg Trading Volume0.00M
52-Week Price Return-74.81%
Tangible BV / Share (Quarterly)$2.17
52-Week High$170.00
EPS Excl Extra (Annual)$-1.29
26-Week Price Return50.18%
Quick Ratio (Annual)35.68x
13-Week Price Return6.94%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)57.37x
Enterprise Value$811.26M
Cash / Share (Annual)$7.87
3-Month Return Std Dev60.86%
ROE (Last FY)-14.91%
Net Interest Coverage (Annual)-3.45x
EPS Basic Excl Extra (Annual)$-1.29
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.98
ROI (TTM)-28.41%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.94
Price vs S&P 500 (52W)-74.37%
Year-to-Date Return11.80%
5-Day Price Return6.26%
EPS Normalized (Annual)$-1.29
ROA (5Y Avg)-50.83%
Month-to-Date Return2.99%
Cash Flow / Share (TTM)$-1.82
EBITD / Share (Annual)$-1.46
LT Debt / Equity (Annual)0.68x
ROI (5Y Avg)-69.75%
LT Debt / Equity (Quarterly)0.18x
EPS Basic Excl Extra (TTM)$-1.98
P/TBV (Quarterly)1.99x
P/B Ratio (Annual)7.29x
Book Value / Share (Annual)$7.79
Price vs S&P 500 (13W)-2.81%
Beta2.16x
Revenue / Share (TTM)$0.00
ROE (TTM)-28.46%
52-Week Low$33.01
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Jul 2022
Aug 2022
Sep 2022
Oct 2022
4.29
4.29
4.29
4.29
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DRUGBright Minds Biosciences Inc. Common Stock | — | — | C | $81.02 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Bright Minds Biosciences develops next-generation serotonin agonists targeting treatment-resistant neuropsychiatric and pain disorders, including depression, PTSD, epilepsy, and chronic pain. The company's approach combines the therapeutic benefits of psychedelic and serotonergic compounds while reducing side effects compared to first-generation treatments. By addressing underlying neurocircuit abnormalities, Bright Minds targets large patient populations with significant unmet medical needs.